Medexus Pharmaceuticals Inc
TSX:MDP

Watchlist Manager
Medexus Pharmaceuticals Inc Logo
Medexus Pharmaceuticals Inc
TSX:MDP
Watchlist
Price: 2.97 CAD -3.88% Market Closed
Market Cap: 96.3m CAD

Medexus Pharmaceuticals Inc
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Medexus Pharmaceuticals Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Medexus Pharmaceuticals Inc
TSX:MDP
Stock-Based Compensation
$456k
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Stock-Based Compensation
$175m
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
3%
Canopy Growth Corp
TSX:WEED
Stock-Based Compensation
CA$7.1m
CAGR 3-Years
-40%
CAGR 5-Years
-48%
CAGR 10-Years
22%
Sundial Growers Inc
NASDAQ:SNDL
Stock-Based Compensation
CA$19.8m
CAGR 3-Years
29%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Stock-Based Compensation
$8m
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Stock-Based Compensation
CA$4.7m
CAGR 3-Years
39%
CAGR 5-Years
20%
CAGR 10-Years
2%
No Stocks Found

Medexus Pharmaceuticals Inc
Glance View

Market Cap
96.3m CAD
Industry
Pharmaceuticals

Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.

MDP Intrinsic Value
8.96 CAD
Undervaluation 67%
Intrinsic Value
Price

See Also

What is Medexus Pharmaceuticals Inc's Stock-Based Compensation?
Stock-Based Compensation
456k USD

Based on the financial report for Sep 30, 2025, Medexus Pharmaceuticals Inc's Stock-Based Compensation amounts to 456k USD.

What is Medexus Pharmaceuticals Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
-24%

The average annual Stock-Based Compensation growth rates for Medexus Pharmaceuticals Inc have been -24% over the past three years .

Back to Top